MET and thyroid gland carcinoma: MET is a receptor tyrosine kinase that promotes cell proliferation through PI3K/AKT signaling and miR-34a is considered to be a tumor suppressor targeting MET, thus XIST promotes the proliferation of thyroid cancer by down-regulating miR-34a and increasing MET [35].